Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

(2016) Elizabeth A. Kuczynski et al.   JNCI-Journal of the National Cancer Institute

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

(2016) Naomi B Haas et al.   LANCET

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

(2016) Sophia Frentzas et al.   NATURE MEDICINE

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

(2016) Elizabeth A. Kuczynski et al.   JNCI-Journal of the National Cancer Institute

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases

(2015) Han-Sin Jeong et al.   JNCI-Journal of the National Cancer Institute

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases

(2015) Han-Sin Jeong et al.   JNCI-Journal of the National Cancer Institute

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

(2014) Manuel Valiente et al.   CELL

Mechanism of tumour vascularization in experimental lung metastases

(2014) Vanessza Szabo et al.   JOURNAL OF PATHOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy

(2013) N S Vasudev et al.   BRITISH JOURNAL OF CANCER

A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs

(2013) E. Guerin et al.   CANCER RESEARCH

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

(2013) John P. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

(2013) Tom Donnem et al.   Cancer Medicine

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

(2011) Nicholas J. Robert et al.   Clinical Breast Cancer

Lack of Angiogenesis in Experimental Brain Metastases

(2011) Edina Bugyik et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling

(2009) Samuel A. Yousem   HUMAN PATHOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

The Vascular Basement Membrane as “Soil” in Brain Metastasis

(2009) W. Shawn Carbonell et al.   PLoS One

Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes

(2008) Peyman Sardari Nia et al.   ANNALS OF THORACIC SURGERY